
Zacks identifies Labcorp (LH) as a strong momentum stock, despite its #3 (Hold) rank, citing its 'A' VGM and 'B' Momentum Style Scores. The healthcare diagnostics provider's shares have gained 9.4% over the past four weeks, supported by eight analysts revising fiscal 2025 earnings estimates upwards by $0.25 to $16.30 per share in the last 60 days, and an average earnings surprise of +2.5%. This combination of strong technicals and positive earnings revisions positions LH as a potential consideration for momentum-driven portfolios.
Labcorp Holdings (LH) presents a compelling case for momentum investors, characterized by a dichotomy between its neutral Zacks #3 'Hold' rank and strong underlying performance indicators. The stock has demonstrated significant recent strength, with its share price increasing 9.4% over the past four weeks. This price action is supported by a positive shift in forward-looking fundamentals, evidenced by eight analysts revising their fiscal 2025 earnings estimates upward within the last 60 days. Consequently, the Zacks Consensus Estimate for FY2025 has increased by $0.25 to $16.30 per share. This positive revision trend, coupled with a historical average earnings surprise of +2.5%, underpins the stock's 'B' Momentum Style Score and its top-tier 'A' VGM Score, suggesting that improving earnings expectations are a key driver of its current trajectory.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment